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Abstract
Mantle cell lymphoma is a clinically heterogeneous disease occurring within a heterogeneous
patient population, highlighting a need for personalized therapy to ensure optimal outcomes.
It is therefore critical to understand the benefits and risks associated with both intensive
and deintensified approaches. In the following review we provide a therapeutic roadmap to
strategically guide treatment for newly diagnosed and relapsed/refractory patients highlighting
pivotal and recently published results involving known and novel therapies.
Ó 2017 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).

Introduction
Mantle cell lymphoma (MCL) is an uncommon B-cell malignancy subtype that was officially classified as a distinct class
of non-Hodgkin lymphoma (NHL) by the revised EuropeanAmerican classification (REAL) in 1994 [1] and characterized
as a mature B cell neoplasm with morphological variants of
* Corresponding author at: H. Lee Moffitt Cancer Center &
Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
E-mail address: jose.sandoval@moffitt.org (J.D. Sandoval-Sus).

diverse clinical behavior by the 2008 World Health Organization classification [2]. It usually accounts for 6% of all NHL in
United States, and 7–9% in Europe [3,4]. New cases of MCL
have increased with a recently reported incidence of 0.64
per 100,000 person years in the US population [5,6]. The
disease is more commonly diagnosed in older men with a
median age at diagnosis of 68 years, and a male/female
ratio of 2.6:1 [5,6]. Epidemiological risk factors are
incompletely defined, with data to suggest both inherited
and exogenous triggers related to the development of this
malignancy [7–11].

http://dx.doi.org/10.1016/j.hemonc.2017.02.003
1658-3876/Ó 2017 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diagnosis
Histologically, MCL is composed of mature monomorphic
small to medium size B cells with indented nuclei frequently
lacking visible nucleoli [2,12]. The 2008 World Health Organization classification described four different morphological variants of MCL: small cell variant that
morphologically mimics small lymphocytic lymphoma; marginal zone-like variant that may resemble marginal zone
lymphoma and clinically presents with massive splenomegaly in >80% of patients [13]; and pleomorphic variant and
blastoid variant with lymphoblast-like cells that have a high
mitotic rate [2]. In the spectrum of MCL morphological variants, the blastoid and pleomorphic types have clinical prognostic significance [2,14,15]. The classic immunophenotype
of MCL includes an intense surface immunoglobulin (Ig)M/
IgD more commonly associated with lambda restriction,
positivity for CD5, CD19, CD20 (bright), CD22, weakly positive or negative CD23, and negative expression of CD10
[2]. Even though the above immunophenotypic presentation
is the most typical, up to 26% of MCL are positive for CD23 at
diagnosis [16]. It is also clinically relevant to acknowledge
the higher prevalence of aberrant CD10 expression and/or
CD5 loss among the blastoid and pleomorphic MCL variants
[13,17,18]. Finally, all MCL cases are BCL2 positive and
almost all express cyclin D1 [2,19–21]. The identifying cytogenetic alteration of MCL is the translocation t(11;14)
(q13;32), which is found in the majority of cases [2,22]. This
genetic event juxtaposes the bcl-1 protooncogene to the Ig
heavy chain locus resulting in cyclin D1 overexpression
[2,11]. Notably, fluorescence in situ hybridization (FISH) is
more sensitive and specific for the detection of cyclin D1
and other variants, rather than conventional cytogenetic
analysis [23–26]. Cytogenetic and FISH evaluation are of
importance when evaluating for blastoid/pleormorphic subtypes with aberrant antigen expression, as bcl1 and bcl2
overexpression can also be seen in some cases of diffuse
large B-cell lymphoma. Certain rare MCL variants lacking
cyclin D1 have been described, and may be identified by
overexpression of the nuclear transcription factor SOX11
[27,28]. Cyclin-D1-negative MCL may show cyclin D2 and
possibly cyclin D3 overexpression and/or translation
instead, with small case series suggesting inferior prognosis
[29].

Disease presentation and initial work-up
The initial presentation of MCL can be variable. Patients can
present in a leukemic phase with marked leukocytosis, with
pancytopenia, or even with localized involvement of unusual extranodal areas such as skin, central nervous system,
or lacrimal glands [12,30]. However, the disease more commonly presents in advanced stages (III/IV) with disseminated lymphadenopathy, splenomegaly, and bone marrow
infiltration. Remarkably, the gastrointestinal (GI) tract is
one of the preferred extranodal homing sites of MCL and
many will show involvement on endoscopy/colonoscopy,
particularly if random biopsies are obtained in the absence
of visible abnormalities [4,31,32]. Other potentially
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involved sites at presentation are the liver and Waldeyer’s
ring [28].
Retrospective studies suggest that up to 30% of newly
diagnosed MCL patients may have an indolent presentation
and do not require immediate treatment [11,33,34]. Clinically, such patients usually debut with modest lymphocytosis, nonbulky lymphadenopathy, splenomegaly, bone
marrow infiltration and/or GI involvement [33–36]. The cellular proliferation marker Ki-67 is usually low (<30%) in
these patients, consistent with an indolent course [37,38].
Serial biopsies of both indolent and classic tumors with evidence of morphological and proliferation changes suggest
that the indolent MCL variant has a different natural history,
and could be part of an initial low-grade disease spectrum
with steady progression towards a more aggressive tumor
[33–35,39]. Retrospective evaluations suggest that those
with slow progression to symptomatic disease (i.e., >12
months before treatment is indicated) may have overall
better prognosis [31,33,35]. It is critical to distinguish indolent tumors from in situ MCL [35]. The natural history of
in situ MCL is not well characterized and in most series,
the diagnosis of in situ cases is only appreciated retrospectively from biopsies obtained prior to the clinical manifestation of MCL [35,40–43]. Nonetheless, in situ MCL usually has
a very long latency period and close follow-up without
active treatment is indicated [35].
To obtain accurate staging and useful prognostic information, initial workup for MCL needs to include a thorough
history and physical examination with detailed documentation of baseline performance status (i.e., Eastern Cooperative Oncology Group score) [44], constitutional symptoms,
lymphadenopathy, hepatosplenomegaly, and/or other possible areas of extranodal involvement [4]. A complete blood
count, peripheral blood flow cytometry, metabolic profile,
b2 microglobulin, and lactate dehydrogenase (LDH) level
should be part of the initial evaluation, as well as HIV, hepatitis B and C serology since almost all current systemic
therapies include anti-CD20 monoclonal antibodies with
the potential for virus-mediated complications [4]. As with
other NHLs, initial staging should include a bone marrow
biopsy with immunophenotyping by flow cytometry, cytogenetics with FISH evaluation, as well as a computed tomography (CT) with contrast of the neck, chest, abdomen, and
pelvis [4]. When available, fluorodeoxyglucose positron
emission tomography (PET)/CT should also be considered
to guide nodal biopsy (to the site with highest uptake) and
to improve detection of extranodal disease manifestations.
Despite the high frequency of GI tract involvement, with
some reports describing incidences as high as 88–92%
[31,32], routine use of upper endoscopy and colonoscopy
usually does not influence initial treatment approach. In
accordance with current guidelines [4,13], we recommend
the use of endoscopy/colonoscopy as part of the initial
workup in patients that have symptoms or signs of GI
involvement or to confirm Stage I/II disease that would
otherwise be treated with localized therapeutic modalities.
Finally, a lumbar puncture to evaluate central nervous system involvement is warranted in patients with neurological
symptoms, blastoid variant MCL and/or high Ki-67 (>50%)
[4,45].

Mantle cell lymphoma

Prognosis
Baseline prognostic characterization was initially established using risk scores validated for low-grade B-cell lymphomas (follicular lymphoma prognostic index; FLIPI) and/
or aggressive lymphomas (International Prognosis Index;
IPI). However, both failed to adequately stratify patients
in different risk subgroups, especially low-risk patients
[13,35,46,47]. In 2008 the European MCL Network developed a tailored prognostic score for MCL: the Mantle Cell
Lymphoma International Prognostic Index (MIPI) [48]. Using
data from >450 patients, four variables emerged as independent prognostic factors for shorter overall survival (OS):
older age, advanced performance status, elevated LDH,
and high white blood cell count, which effectively stratified
patients into three different risk groups: low, intermediate,
and high. After a median follow-up of 32 months, the lowrisk group had not reached a median OS (5-year OS, 60%),
while patients in the intermediate- and high-risk groups
had a median OS of 51 months and 29 months, respectively.
Addition of the Ki-67 proliferation index at diagnosis to the
MIPI score may increase the discriminatory power [49,50].
Research is currently ongoing to improve interobserver
reproducibility of Ki-67, which may further increase its
prognostic utility [51,52]. The MIPI score has been validated
by different groups, however; prognostic estimations using
the MIPI have only been validated prior to first therapy,
and the score is not predictive of response to any particular
chemoimmunotherapeutic regimen [35]. Other disease features, including gender, the presence of B symptoms, and
b2 microglobulin may add further to differentiate lowand intermediate-risk groups [53,54]. Anecdotally, the presence of B symptoms appears to improve the discrimination
of the indolent MCL variant, which may frequently present
with modest leukocytosis in older patients. Finally, there
is emerging evidence that loss and/or mutation of specific
genes, including TP53 and CDKN2A, may also inform prognosis, and are associated with poor outcomes in spite of
aggressive therapy [55].
Outside clinical trials we do not recommend to use MIPI
as a tool to guide therapeutic decisions in patients with
newly diagnosed MCL. Alternatively, those with higher proliferative rates as defined by Ki-67 immunostaining, may
benefit from more intensive treatment approaches,
although the optimal approach is not yet defined.

Risk-directed treatment: a glimpse of
personalized therapy in MCL
Therapies in MCL have classically been envisioned around
the goal of obtaining longer remission by the way of deeper
initial responses using intensive induction regimens. The
exquisite chemosensitivity of MCL to a variety of front-line
agents encourages this hypothesis, especially in the young
and/or healthy population, where Phase II studies with multiagent regimens and dose escalation of cytotoxic compounds seem to prolong progression-free survival (PFS),
and potentially extend patient survival [35,56–60]. Regardless of the potency of the initial regimen, MCL remains an
incurable disease with a median duration of remission of
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around 5 years and OS of 3–10 years across most clinical trials [13]. More recently, alternative cytotoxic agents and
newer targeted molecules have proven to be effective in
clinical trials directed to patients with relapsed/refractory
(R/R) disease and/or elderly individuals [61–66]. Precision
agents might set the stage for a shift in the treatment of
MCL in which less toxic therapies with high response rates
are taken to the front-line setting in all patients regardless
of their chronological and/or functional age.

Treatment of indolent MCL
Given that MCL is an incurable hematological malignancy
destined to relapse, monitoring asymptomatic patients with
favorable biological features (e.g., nonblastoid histology,
low Ki-67 proliferation rate, and low MIPI) under a watchful
waiting approach is an emerging therapeutic strategy
[33,34]. Although we acknowledge there is an absence of
randomized prospective data, we believe this approach is
reasonable, regardless of age at diagnosis or disease stage,
given our own institutional experience, as well as that
gleaned from other published retrospective data sets
[33,67]. We suggest that asymptomatic patients with favorable clinical and biological characteristics can be followed
every 3–6 months with a complete history and physical
exam, complete blood count, complete metabolic panel,
and LDH. Albeit there is lack of data to support the use of
contrasted CT scans and/or PET/CT imaging in this population, these images can potentially be done under the same
proposed surveillance schedule, and may be tailored
according to the clinical evolution of individual patients.
As in chronic lymphocytic leukemia, systemic treatments
should be started once patients develop constitutional
symptoms, rapidly growing or symptomatic lymphadenopathy and/or splenomegaly, or disease-related cytopenias
[13,35]. It also has been suggested that oncologists and
patients who do not feel comfortable with only vigilant disease surveillance can consider monotherapy with weekly
rituximab for 4 weeks, followed by maintenance every 2
months [35,68]. Importantly, this recommendation has not
been systematically studied in the indolent MCL population
in contrast to indolent follicular lymphoma [69,70]. Accordingly, several questions remain unanswered, including the
duration of rituximab therapy (lifelong vs. 2 years), appropriate rituximab treatment strategy (rituximab retreatment
at time of asymptomatic progression vs. rituximab maintenance), safety of rituximab maintenance (RM), and the
cost-effectiveness of this approach [69,70]. In patients with
symptomatic splenomegaly characterized by left upper
quadrant pain, early satiety and cytopenias related to
hypersplenism, palliative splenectomy has been shown to
delay the initiation of chemotherapy by several years
[71,72]. This surgical intervention can be an especially
attractive option for patients who otherwise have limited
systemic evidence of MCL, akin to splenic marginal zone
lymphoma.
An important clinical caveat is to distinguish indolent
MCL with leukocytosis from the aggressive leukemic phase
of MCL most commonly characterized by hyperleukocytosis
(often >50,000/mL), constitutional symptoms, elevated
LDH, progressive splenomegaly and symptomatic cytopenias
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[73–75]. These patients will often present with rapid doubling time of the white blood cell count, in addition to
mutation or loss of p53 [75,76]. Aggressive chemotherapy
is frequently used, although there is emerging data for the
use of lenalidomide and rituximab in this context [77]. However, if patients have deteriorated at diagnosis and are not
candidates for any available therapies, palliative splenectomy can be a therapeutic alternative for symptomatic control [35,78].

Treatment of limited stage MCL (Stage I and
nonbulky Stage II)
Limited presentation of symptomatic MCL is rare (6–17% of
newly diagnosed patients) with available treatment information based on retrospective series and expert opinions
[4,79,80]. It is our recommendation that, before engaging
in active therapy of these patients, extensive disease
involvement (Stage III/IV) needs to be ruled out by a thorough staging strategy including imaging (PET/CT scan), bone
marrow biopsy with a sensitive flow cytometry technique,
and GI diagnostic studies (endoscopy and colonoscopy)
[4,35]. A retrospective analysis by Leitch et al. [81] involved
26 symptomatic MCL patients with Stage I and nonbulky
Stage IIA disease treated with chemotherapy and with or
without involved field radiotherapy (IFRT). Patients receiving IFRT with or without chemotherapy (n = 17) had a 5year PFS of 68%, compared with 11% for those not receiving
radiation therapy (n = 9, p = 0.002) with no disease progression after 6 years of follow-up. Also, the 6-year OS after
IFRT plus chemotherapy was 71%, compared to 25% in
patients treated only with chemotherapy (p = 0.13) [81]. A
more contemporary retrospective series from Princess Margaret Hospital in Toronto, Canada described 21 patients
with limited stage MCL that were treated with curative
intent [79]. Of note, this population was less homogeneous,
including five patients with blastoid MCL. Fifteen patients
received concurrent cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-like chemotherapy with
IFRT (35 Gy), two were treated with just IFRT and two were
treated with chemotherapy followed by autologous stem
cell transplantation (ASCT). Median PFS and OS were 3.2
years and 6.4 years, respectively, with Stage II and blastoid
variant being negative prognostic factors for systemic
relapses in univariate analysis [79]. Remarkably, all of the
available series suggest that OS is not affected in patients
treated initially with locally directed therapy, underscoring
that salvage chemotherapy at the time of disease progression retains efficacy. In short, for patients with confirmed
Stage I/nonbulky Stage II symptomatic disease, we recommend treatment with IFRT (30–36 Gy) with or without
chemotherapy, in accordance with recently published
guidelines [4]. Our own approach is to favor concurrent
chemoimmunotherapy (CIT) in patients with pronounced B
symptoms, as well as with bulky lymphadenopathy at presentation. Finally, patients achieving complete remission
(CR) should be followed every 3–6 months for the first 5
years and yearly (or as clinically indicated) thereafter.
Patients with R/R disease should ideally be treated with systemic CIT regimens commonly used in those with advanced
disease stages (bulky Stage II and Stage III/IV) [4].
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First-line treatment of advanced stage MCL in
elderly and unfit patients: precision above
intensity
The design of treatment approaches in newly diagnosed
older and/or infirm patients has focused on the deintensification of induction therapy, with the goal of minimizing toxicity, coupled with extended maintenance approaches to
maximize duration of response (Table 1). The advent of targeted agents with activity in MCL has provided the necessary
ammunition to achieve these objectives such that we can
now treat this population with the realistic opportunity to
improve disease related symptoms and survival.
Rituximab was one of first rationally designed therapies
that showed promising single-agent activity in MCL. In Phase
II clinical trials, single-agent rituximab showed an overall
response rate (ORR) of 22–38% with CR of 2–15% across
all studies [68,82–85]. Based on positive preclinical synergistic experiments, rituximab was added to the CHOP
chemotherapy backbone and tested in a single-arm Phase
II clinical trial of 40 newly diagnosed MCL patients [86]. In
spite of high ORR/CR (96% and 48%, respectively) as well
as a complete molecular response (negative PCRdetectable BCL-1/IgH or clonal products in peripheral blood
or bone marrow) of 36%, median PFS was short, at 16.6
months with no discernable benefit for those with molecular
CR (16.5 vs. 18.8 months) [86]. These results led to a pivotal
randomized Phase II trial by the German Low Grade Lymphoma Study Group that compared R-CHOP to CHOP in
122 previously untreated patients [87]. A significant
improvement in ORR (92% vs. 75%, p = 0.0139), CR (33% vs.
8%, p = 0.0008) and median time to treatment failure
(TTF) (21 months vs. 14 months, p = 0.0131) was observed
with the R-CHOP regimen; no differences were seen in PFS
and OS between the two groups. It is notable that TTF
was measured from the time of first treatment, while the
PFS calculation was done from the time of treatment completion only in patients with partial response (PR) and/or
CR; hence, PFS in this study was equivalent to duration of
response [87]. Based on this information, we might infer
that the most valuable role of rituximab is to sensitize
patients with refractory tumors to the chemotherapy backbone [35]. Further studies have confirmed the high ORR
when rituximab is added to CHOP, in turn reflected by prolonged disease control. In fact, both a meta-analysis of
seven randomized controlled trials and a robust retrospective analysis of >600 patients with a mean age of 75 years
have suggested that front-line CIT containing rituximab
might improve OS of newly diagnosed MCL patients [88,89].
Fludarabine, a purine analog with established clinical
effectiveness in chronic lymphocytic leukemia/small lymphocytic lymphoma [90,91], has also been used in elderly
MCL patients [92,93]. The combination of fludarabine with
cyclophosphamide and rituximab (FCR) resulted in CR of
65% along with prolonged PFS and OS (31 months and 46
months, respectively) [94]. Nonetheless, mortality related
to other causes (i.e., infections and secondary malignancies) was high in patients treated with the combination
(29%). More recently, a Phase III randomized study in elderly
patients (median age = 70 years) done by the European MCL
group compared FCR to R-CHOP in treatment-naı̈ve patients

Note. CR = complete remission; IFN = interferon; N/A = not available; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; BR = bendamustine, rituximab; RBAC = rituximab, bendamustine, cytarabine; R-CF = rituximab, cyclophosphamide, fludarabine; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Ri-BVD =
Rituximab, bendamustine, bortezomib, dexamethasone; RM = rituximab maintenance; TTF = time to treatment failure; VcR-CVAD = bortezomib, rituximab, hyperfractionated
cyclophosphamide, vincristine, doxorubicin, dexamethasone; VR-CAP = bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone.

BRvs. R-CHOP
VR-CAP vs. R-CHOP
R-BAC
RiBVD
Rummel et al./III [104]
Robak et al./III [99]
Visco et al./I/II [109]
Gressin et al./II [111]

94
487
20
76

93 vs. 91
92 vs. 89
100
86

40 vs. 30
53 vs. 42
95
74

35 mo vs. 22 mo (TTF)
24.7 mo vs. 14.4 mo (PFS)
95% 2-y (PFS)
69%, 2-y (PFS)

77%, 2-y (both arms)
62% vs. 47%, 4-y (87% R-CHOP
+ RM vs. 63% RCHOP + IFN-a)
No difference
64% vs. 54% 5-y
NA
80%, 2-y
21 mo vs. 14 mo (TTF)
28 mo vs. 26 mo (TTF)
34 vs. 7
34 vs. 40
94 vs. 75
86 vs. 78
R-CHOP vs. CHOP
R-CHOP vs. R-CF ? IFN-a vs. RM
Lenz et al./III [87]
Kluin-Nelemans et al./III [95]

122
485

CR (%)
ORR (%)
No. of patients
Regimen

Table 1
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Clinical trial/phase

Clinical outcomes of selected first-line regimens for older ( 65 years) or unfit MCL patients.

Efficacy outcomes

Median OS

Mantle cell lymphoma

[95]. Although CR rates were similar between the two
groups (40% and 34%, respectively; p = 0.10), the 4-year
OS was superior in the R-CHOP group (62% vs. 47%;
p = 0.005), related to a higher rate of deaths associated
with lymphoma relapse (20% vs. 26%), as well as infectious
complications and secondary cancers in the FCR arm. This
study also included a second randomization of maintenance
with rituximab versus interferon a in patients who
responded to induction therapy [95]. The best response
was seen in the group allocated to RM following R-CHOP
induction (4-year PFS and OS 57% and 87%, respectively).
This landmark trial provided strong evidence for prolonged
PFS in MCL with RM, and delineated a paradigm shift in
the care of elderly patients, highlighting that lowerintensity maintenance strategies could yield outcomes comparable to those seen in younger patients treated more
intensively [15,58–60].
Driven by the idea of prolonging disease remission, the
proteasome inhibitor bortezomib was recently introduced
to the first-line setting of MCL treatment. Based upon
encouraging clinical outcomes of bortezomib in the relapsed
setting [62,96–98], investigators of the recently reported
Phase III LYM-3002 study substituted vincristine for bortezomib in the classic R-CHOP regimen (VR-CAP) and compared it in a randomized fashion to R-CHOP [99]. Although
response rates were similar between the study groups, CR
rates were significantly higher in the VR-CAP group compared to patients treated with R-CHOP (53% vs. 42%, respectively), which reflected in a significant longer PFS (24.7
months vs. 14.4 months, respectively) with a hazard ratio
(HR) favoring the bortezomib-based study arm (0.63,
p < 0.001). Importantly, duration of response (DOR) was
maintained across all MIPI categories and Ki-67 values. Also,
while patients treated in the R-CHOP group achieved a median OS of 56.3% after a median follow-up of 40 months, the
median OS for the VR-CAP group has not been reached
(HR = 0.80; p = 0.17). Notably, a high proportion of Asian
Americans were treated on this study (32%), which suggests
a unique advantage to proteasome-based approaches in this
population [99]. Finally, although peripheral neuropathy
was comparable among groups, VR-CAP patients required
more frequent platelet transfusions due to higher grade
3/4 thrombocytopenia (57% vs. 6%), more frequent use of
growth factors and antibiotics due to higher rates of severe
neutropenia (85% vs. 67%) and infectious episodes (21% vs.
14%), but without differences in febrile neutropenia. This
trial, as well as other MCL studies [100], illustrates the high
clinical activity of bortezomib-based therapies in newly
diagnosed MCL, although combination with new synergistic
agents warrants further exploration.
Another agent that has shown significant clinical activity
and favorable toxicity profile in MCL is bendamustine, a
unique nitrogen mustard-derivative alkylating agent with a
purine-like benzimidazole ring [35,101]. This compound
was initially tested in relapsed MCL through several Phase
II studies showing encouraging ORR (>75%) and CR rates
(38–58%), translating in PFS as high as 1.5 years, even in
elderly patients that had undergone multiple lines of therapy [61,102,103]. These data pre-empted a randomized
Phase III European study (StiL trial) in which bendamustine
plus rituximab (BR) was compared against R-CHOP in newly
diagnosed indolent NHL lymphomas and MCL [104]. Of the
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study population, 94 patients (median age = 70 years) had
MCL. The study showed similar ORR (>90%) for both treatment arms, although higher CR rates and longer PFS were
seen in the BR group (PFS = NR vs. 42.3 months,
p = 0.0072). No differences in OS were found between treatments, which might have been confounded by patient crossing over to the BR arm after disease progression on R-CHOP.
Notably, a follow-up study of RM  2 years after BR was
recently presented, and suggests that RM may be of less
benefit after BR. However, a higher rate of progressive disease (and lymphoma associated death) in the BR/RM arm, as
well as a rapid drop-off in event-free survival (EFS) and DOR
at 36 months merits further exploration before any definitive conclusions can be drawn [105]. A valuable outcome
seen in the elderly patients treated within this trial was
the remarkably low rate of side effects in the BR group,
including lower rates of neutropenia, paresthesia, stomatitis, and mucositis [104]. Flinn et al. [106] performed a large
international noninferiority trial to confirm these data in a
broader population. In this study, treatment-naı̈ve patients
with low-grade NHL or MCL were equally randomized to BR
versus a rituximab-containing regimen (R-CHOP/R-CVP
(rituximab, cyclophosphamide, vincristine and prednisone))
based on the treating physician criteria [106]. Of note, in
this study there were fewer MCL patients (n = 74) and they
were younger (median age = 63 years). The ORR was similar
between the two study groups; however, CR rates among
MCL patients treated with BR were higher (50% vs. 27%;
p = 0.018). At the time of publication, time-to-event results
were not mature to evaluate PFS and OS, although no differences were seen at this early time point due to unexpected
deaths among those treated with BR. Similarly, while neurological and hematological toxicities were higher in the RCHOP/R-CVP patients, the incidence of nausea/vomiting,
poor appetite, fevers, and chills was higher in the BRtreated group [104,106].
Given the widely recognized benefit of cytarabine (AraC) in the induction regimens of younger MCL patents
[15,107,108], incorporation of this pyrimidine analog at
intermediate doses to the BR combination in the front-line
therapy of elderly patients (R-BAC) has also been explored.
This combination demonstrated impressive results in a small
Phase I/II trial including both untreated and relapsed MCL
with a median age of 70 years. Specifically, among
untreated patients, 100% ORR (CR 95%) was observed, while
among those with relapsed disease the ORR was 80% (70%
CR). This translated into a 2-year PFS of 95% and 70% among
untreated and relapsed patients, respectively [109]. A
follow-up Phase II trial with further attenuation of Ara-C
demonstrated improvement in hematological toxicity and
preserved CR rate (91%). However, outcomes remained inferior in those with proliferative MCL (Ki-67 > 30%), for whom
2-year EFS was 44% (vs. 100% in remainder) [110]. An alternative approach adding subcutaneous bortezomib and dexamethasone to the BR backbone (RiBVD) was recently
explored. In this study, 74 newly diagnosed MCL patients
with a median age of 73 years were treated with six cycles
of RiBVD, and subsequently followed without maintenance.
After all cycles were completed, this regimen demonstrated
a CR/CR unconfirmed of 74% (74% molecular response in the
bone marrow), which translated into a 2-year PFS and OS of
69% and 80%, respectively [111].

J.D. Sandoval-Sus et al.
Striving for biological-based therapies, or chemotherapyfree regimens, different types of NHL have been treated
with the combination of rituximab plus the immunomodulatory drug (IMID) lenalidomide. With previous positive experiences using lenalidomide in R/R MCL that will be further
discussed [112], and encouraging data of rituximab/
lenalidomide combination (R2) in the front-line treatment
of indolent NHL [113], this nonchemotherapy doublet was
tested in a previously untreated MCL population. Ruan
et al. [114] recently reported the results of a Phase II multicenter study of 38 newly diagnosed symptomatic MCL
patients treated with R2. The patient’s median age was 65
years and baseline clinical characteristics were similar.
Treatment consisted of 12 cycles of induction therapy with
lenalidomide (20 mg/day  21 days) plus rituximab (4
weekly doses, followed by 1 dose every other cycle), followed by a maintenance phase (lenalidomide 15 mg/day  21 days plus rituximab every 2 months). After a
median follow-up of 30 months, patients achieved an
impressive ORR of 92% (CR 64%), along with high 2-year
PFS and OS (85% and 97%, respectively). These outcomes
demonstrated the feasibility of a low-intensity biological
regimen in MCL, coupled with high responses and durable
disease control.
Successful outcomes seen in the elderly and unfit population with first-line deintensified regimens coupled with
maintenance strategies, may equate to the benefits of prolonged disease remission obtained with intensified
chemotherapy with or without ASCT. While it remains
unclear whether prospective evidence with RM will demonstrate a clinical benefit independent of chemotherapy
choice, a recent meta-analysis of >430 MCL patients treated
in randomized trials demonstrated an improvement in PFS
[HR 0.60, 95% confidence interval (CI) 0.44–0.82] and an
apparent lower mortality (HR 0.67, 95% CI: 0.37–1.69),
although the combined trials were heterogeneous with
regard to OS (I2 = 54%) [115]. This evidence reinforces our
recommendation of using a lower-intensity CIT regimen,
such R-CHOP, BR, R2, or VR-CAP followed by RM in responding patients that achieve at least a PR. Due to the positive
strides made in B-cell tumor biology, leading to the generation of active antilymphoma agents, efforts are underway to
evaluate the effect of novel therapies both in combination
with front-line therapy and as maintenance for elderly and
unfit MCL patients. This is exemplified by the ongoing US
intergroup E1411 study of BR ± bortezomib followed by
rituximab ± lenalidomide (ClinicalTrials.gov-NCT01415752).

First-line treatment for advanced-stage MCL in
young and fit patient: high intensity for all?
While no regimen has proven to yield an OS benefit for
patients with advanced MCL, upfront therapy of young
(65 years) and fit (Eastern Cooperative Oncology Group
performance status 1 with preserved end-organ function)
patients have centered on the premise of achieving deep
responses with higher-intensity treatments (Table 2). After
demonstrating synergistic activity with Ara-C and cisplatin
for the treatment of refractory NHL [116], French researchers were the first to showcase the notion that aggressive
therapies may specifically benefit young patients with
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Note. ASCT = autologous stem cell transplantation; CR = complete remission; HDAraC = high-dose cytarabine; MTX = methotrexate; NR = not reached; ORR = overall response rate; OS =
overall survival; PFS = progression-free survival; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-DHAP = rituximab, dexamethasone, high-dose cytarabine,
cisplatin; R-HyperCVAD = rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine; RM = rituximab maintenance; TTF = time to
treatment failure; VcR-CVAD = bortezomib, rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; VP-16 = etoposide.

68% 8-y OS
69% 5-y OS
71% 5-y OS
64% 5-y OS
70% 6-y OS
6.8 y vs. NR
82.2% vs. 64.6% 4-y OS
46% 8-y TTF
53% 5-y PFS
61% 5-y PFS
56% 5-y PFS
66% 6-y PFS
3.8-y PFS vs. 7.3-y PFS
78.9% vs. 61.4% 4-y EFS
87
55
72
69
54
63 vs. 61
77.3
97
86
83
88
96
98 vs. 99
89.3
R-HyperCVAD w/o ASCT
R-HyperCVAD w/o ASCT
R-HyperCVAD w/o ASCT
R-CHOP + MTX/R + HDAraC + VP-16 ? ASCT
R-Maxi-CHOP + HD AraC ? ASCT
R-CHOP ? ASCT vs. R-CHOP/R-DHAP ? ASCT
R-DHAP ? ASCT ? RM vs. placebo
Romaguera et al./II [56,107]
Bernstein et al./II [58]
Merli et al./II [118]
Damon et al./II [120]
Geisler et al./II [57]
Hermine et al./III [121]
Le Gouill et al./III [123]

97
49
60
77
160
455
299

ORR (%)
No. of patients
Regimen

Table 2

Clinical trial/phase

Clinical outcomes of selected first-line regimens for young ( <65 years) or fit MCL patients.

CR (%)

Efficacy outcomes

OS

Mantle cell lymphoma

MCL. They treated 25 MCL patients who failed to achieve a
CR after four cycles of CHOP with two or three cycles of
dexamethasone, high-dose Ara-C and cisplatin (DHAP),
achieving a CR conversion of 84% [117]. DHAP chemotherapy
also served as a bridge to ASCT in 23 of these patients, culminating in a favorable disease control (3-year OS 90.4%).
Similar data was generated by the MD Anderson Cancer Center, who introduced the R-HyperCVAD/M-AraC regimen for
the treatment of MCL. In this Phase II trial they demonstrated an ORR of 97%, with an accompanying CR rate of
87% [56,107]. Among younger patients, these high response
rates were accompanied by prolonged remissions
(TTF = 4.6 years) and an 8-year OS of 68%. Notably among
older patients (>65 years), necessary decreases in relative
dose intensity were accompanied by shorter remissions
and survival (8-year OS 33%), reinforcing the benefit of
intensified therapy in younger/fit patients [107]. At least
two other Phase II multicenter clinical trials have confirmed
the high activity and, in particular, the hematological toxicity of R-HyperCVAD/MA [58,118].
In an effort to improve the duration of remissions and
survival, further studies were developed in which intensive
induction was followed in turn by myeloablative consolidation chemotherapy and autologous stem cell transplantation. In the landmark Phase II clinical trial by the Nordic
group, 160 newly diagnosed young patients with MCL were
treated with six alternating cycles of Maxi-CHOP (cyclophosphamide 1200 mg/m2 and doxorubicin 75 mg/m2) and rituximab with high dose Ara-C [15]. Responders received highdose chemotherapy with ASCT. This regimen yielded a 96%
ORR with a 54% CR rate. After a median follow-up of 11.4
years the Nordic protocol achieved a median PFS of 8.5
years and a median OS of 12.7 years [119]. Unfortunately,
as had been observed with HyperCVAD, no plateau in the
PFS or OS was observed [57]. CALGB 59909 used an abbreviated CIT combination consisting of two cycles of R-CHOP
(cyclophosphamide 2 g/m2) with methotrexate (300 mg/
m2) followed by rituximab, high-dose Ara-C and etoposide,
and ASCT consolidation with post-transplant rituximab  2
doses [120]. This approach yielded a 5-year PFS and OS of
56% and 64%, respectively, comparable in terms of both efficacy and toxicity with HyperCVAD/MA and Maxi-CHOP [35].
Given the success previously observed with R-CHOP/RDHAP, a large prospective randomized study was conducted
comparing this induction regimen to R-CHOP, followed in
turn by ASCT. Preliminary analysis of the results showed
that both groups had a similar ORR after induction (90%
vs. 94%; p = 0.14), but with significantly higher CR/CR
unconfirmed (39% vs. 55%; p = 0.0005) and molecular remission rates (47% vs. 79%, p < 0.0001) in the R-CHOP/R-DHAP
arm. The R-CHOP/R-DHAP arm similarly demonstrated a
longer TTF (9.1 years vs. 3.9 years; p = 0.038), but similar
OS (5-year OS 76% vs. 69% p = 0.12). It is important to note
that differences in conditioning therapy between the two
groups could have likewise influenced these endpoints
[35,121,122].
Finally, it is worth mentioning emerging data that suggests a possible benefit of RM (given every 2 months for 3
years) following autologous transplantation. At the 2016
ASH annual meeting, data from a randomized trial was presented in this regard, which demonstrated a benefit in EFS
(HR = 0.46, p = 0.0016), PFS (HR = 0.4, p = 0.0007), and OS
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(HR = 0.5, p = 0.045) in favor of RM [123]. Also presented at
this meeting were data using a pre-emptive, rather than
prophylactic, approach to RM in MCL following autologous
transplantation. In this study, patients were followed for
molecular relapse, at which time they could receive 1
cycles of rituximab (given as 4-weekly doses). Remission
was similarly prolonged, with patients showing a median
of 55 months from first molecular relapse to frank clinical
relapse [124]. These data suggest a reappraisal of RM after
autologous transplantation, and furthermore, lay the
groundwork for a pending cooperative group trial comparing
RM with autologous transplantation.
Based on the perceived benefits of deep responses and
prolonged disease control, most front-line therapeutic
strategies in young healthy MCL patients have tried to bundle ASCT after the first complete remission (CR1). Since
patients failing to achieve major disease remission are usually not considered for ASCT and experience faster relapses,
this suggests that the best induction chemotherapy is one
that achieves the deepest disease control. As an example,
some groups have suggested that, obtaining molecular
remission (negative minimal residual disease) after induction with CIT correlates with prolonged disease control,
and is a more powerful predictor for disease relapse than
other baseline risk factors (i.e., MIPI) [125,126]. However,
neither the role of front-line stem cell rescue, nor the most
appropriate pretransplant induction regimen has been
appropriately tested in a randomized fashion, leaving us
with management uncertainties. For example, a retrospective analysis of the NCCN NHL database published in 2012,
which included 167 MCL patients under the age of 65 years,
implied that ASCT improved clinical outcome only in
patients previously treated with less-intense induction regimens [127]. After a median follow-up of 3 years, no significant differences were seen between HyperCVAD/MA and
HyperCVAD/MA followed by ASCT and R-CHOP followed by
ASCT in terms of 3-year PFS (58%, 55%, and 56%, respectively). In contrast, patients treated only with R-CHOP had
a significantly lower PFS compared to individuals treated
with R-HyperCVAD with/without ASCT (p = 0.04 and
p = 0.01, respectively). Nonetheless, ASCT-backed regimens
did not show any OS advantage over R-CHOP. The above
clinical outcomes do not take into account rituximab maintenance strategies that, although not directly comparable,
have yielded similar disease control rates with lower side
effect rates [95].

R/R MCL: making a difference through
biological innovation
Endeavors to improve the outlook of patients with MCL are
undeniable and have proven to be successful. Nonetheless,
a high proportion of patients will eventually relapse or present with refractory disease, despite intensive and/or prolonged CIT. R/R MCL is challenging, as current
chemotherapy regimens yield low response rates
(CR < 30%) with short remission duration [4]. By the end of
2016, there were only three agents approved for treatment
of R/R MCL in the US and a clear standard of care for these
patients has not been established [4,13,128,129]. We should
acknowledge that there are some patients in whom relapsed
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disease is initially asymptomatic and can potentially be closely followed without treatment; this is especially applicable in the elderly and/or unfit population [13]. However,
these asymptomatic presentations have not been well characterized by any studies and a active surveillance approach
should be adopted on a case-by-case basis with caution.
Regarding CIT approaches, second-line regimens utilizing a
different combination of agents from the ones used in the
front-line setting, can be considered. We have already
alluded to the efficacy of the BR combination, which can
induce response rates in more than three-quarters of R/R
MCL patients with low proliferative rate, accompanied by
durable remissions in excess of 50% in selected trials
[61,102]. In the original 2005 trial by Rummel et al. [61],
BR yielded an ORR of 92% (CR of 60%) in 63 R/R MCL
patients. In another Phase II study, BR showed an ORR of
92% (CR 42%) in a similar, although smaller (n = 12), MCL
population [102]. The StiL trail reinforced the positive
results of this CIT combination in a larger randomized setting. In this clinical trial, >200 patients with R/R indolent
NHL and MCL were treated with either BR or fludarabine/
rituximab [130]. Among these patients, 20% (n = 44) had
MCL. After a median follow-up of 8 years, BR demonstrated
superior CR and PFS compared to fludarabine/rituximab
(38.5% vs. 16.2%, p = 0.0004 and 34 months vs. 12 months;
p < 0.0001, respectively) with an associated better OS (9
years vs. 4 years; p < 0.01, respectively) [130]. After
acknowledging these enthusiastic reposes obtained with this
doublet, we also need to recognize that BR has long-term
toxicities with almost 15% of patients developing secondary
malignancies (5 patients with secondary hematological neoplasia), possibly related to alkylator-driven myelotoxic
effects in conjunction with lingering suboptimal cellular
immunosurveillance. As previously described, the incorporation of Ara-C onto a BR backbone (R-BAC) was accompanied by high response rates with manageable toxicity and
largely preserved dose intensity [109].
The last decade of research has yielded targeted and
effective therapies for MCL. The proteasome inhibitor
bortezomib reflects the first approved drug in the evolution
of therapy for this NHL. Its role in chemotherapy combinations has already been briefly summarized, and other novel
combinations are anticipated. The activity of bortezomib as
a single agent for R/R MCL was defined by the Phase II PINNACLE study wherein 155 patients with R/R disease were
treated with intravenous bortezomib until progression.
The ORR with single agent bortezomib was 33%, with 8%
showing a CR [62]. More importantly, remission was accompanied by nearly a 16-month improvement in OS at 2 years
[96]. The second generation proteasome inhibitors, such
as carfilzomib, may provide novel means to circumvent
anticipated treatment associated neuropathy, while mainteining similar therapeutic benefits.
The impact of IMIDs in MCL was first appreciated in a
small Phase II study of thalidomide given with rituximab.
In this study of 16 patients, the researchers observed an
ORR of 81% (CR 31%) and accompanying median PFS of
20.4 months [131,132]. While highly active, thalidomide
was commonly complicated by fatigue, neuropathy, and
thrombotic events, prompting further larger studies with
the second-generation IMID lenalidomide [35]. The antiMCL activity of lenalidomide monotherapy was initially seen
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among R/R MCL patients treated in the Phase II NHL-002 and
NHL-003 trials, where an ORR of 35–53% (CR 12–20%) and
an accompanying DOR of 13.7–16.3 months were observed
[133–135]. The MCL-001 study focused on 134 more heavily
pretreated MCL (median prior therapies = 4; 60% bortezomib
refractory), and provided the foundation of its US Food and
Drug Administration approval in 2013 [112]. Specifically, the
authors observed a 28% ORR (7.5% CR) with corresponding
DOR of 16.6 months. These responses were consistent across
subgroups according to baseline characteristics, with the
exception of patients with high baseline LDH in whom
responses were less frequent. An exploratory analysis of
patients with available Ki-67 treated in the MCL-001 trial
suggested that lenalidomide was active in patients with
both low and high baseline Ki-67, although a lower baseline
proliferation index (<30%) was associated with better DOR
and OS [64]. As with bortezomib, the success of singleagent therapy has prompted to study lenalidomide in combination with other therapies. The combination of lenalidomide and rituximab has shown considerable promise in
both the front-line and the R/R setting [13,112,114]. Among
R/R patients the combination improved the ORR (57% with a
CR of 36%), culminating in a median DOR of 18.9 months
[136].
Preclinical studies using MCL cell lines and patientderived tumor cells from treatment-naı̈ve patients have suggested that activation of the PI3K/ATK/mTOR pathway may
play a fundamental role in disease pathogenesis [137].
Accordingly, mTOR inhibitors have been tested in the R/R
MCL setting with modest single-agent activity, particularly
when compared with gemcitabine- or fludarabine-based
therapies [35,138–140]. As has been observed with other
agents, responses may be further improved when given
together with other compounds as recently observed from
the combination with bendamustine and rituximab [141].
A strategy with well-documented durable clinical activity
and favorable toxicity profile in follicular lymphomas is antiCD20 radioimmunotherapy (RIT) [142]. This approach was
initially tested by the MD Anderson group in a small pilot
study of 34 heavily pretreated older patients (median
age = 68 years) with R/R MCL [143]. After a single dose of
yttrium-90 ((90Y)-ibritumomab, 31% achieved a CR, with
an EFS of 6 months and a OS of 21 months. Patients with
bulky disease and RIT resistant disease (<PR post-RIT) had
inferior survival outcomes. The European MCL network also
investigated the role of RIT in a similar population through a
Phase II clinical trial (MCL-3) that included 48 R/R MCL
patients with adverse risk factors, including elevated LDH
and higher MIPI scores [144]. Importantly, patients with
bulky (>5 cm) and multicentric (>3 involved areas, each
>3 cm) tumor received a short course of induction CIT (3
cycles) before the dose of 90Y-ibritumomab. Thirty-two
patients received induction CIT (50% with BR), and the
entire group was treated with 90Y-ibritumomab. The ORR
was 61% (CR 32%) and responses were superior in the group
that received induction therapy (ORR = 72% and CR 38% for
the induction group). After a follow-up of 2 years, the median PFS and OS were 6 months and 25 months, respectively.
As expected, these outcomes were better in the induction
group and the clinical response to RIT significantly modified
survival outcomes. Finally, RIT had a toxicity profile mainly
characterized by myelosuppression with grade 3/4 cytope-
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nias seen in less than a third of patients. Considering the
comparable activity of single-agent 90Y-ibritumomab to
other agents used in R/R disease (e.g., temsirolimus and
bortezomib), it could potentially play a role in this population. However, these results are clearly eclipsed by the high
single-agent activity and benign toxicity profile of the newly
approved tyrosine kinase inhibitor, ibrutinib, in R/R MCL.
A more comprehensive understanding of the B-cell
receptor (BCR) and its downstream effects on the differentiation, proliferation, migration, and survival of B-cell
malignancies has led to new effective therapeutic possibilities [145]. Bruton’s tyrosine kinase (BTK), spleen tyrosine
kinase, and phosphatidylinositol 3-kinase d are targetable
kinases along the BCR intracellular pathway [145,146]. Ibrutinib, previously known as PCI-32765, is a first-in-class oral
BTK inhibitor that irreversibly inhibits downstream BCR signaling with certain specificity for neoplastic NHL cells
[145,147–149]. Importantly, ibrutinib not only inhibits proliferation and attenuates tumoral B-cell survival, but also
impairs the ability of lymphoma cells to home to their protective niche in lymphoid tissues or bone marrow
[145,146,150–152]. In the first in human Phase I clinical
trial using this molecule, escalating ibrutinib doses were
tested in 56 patients with a myriad of R/R NHL (9% had
MCL) [153]. The MTD was established at 560 mg/day with
a toxicity profile characterized mostly by manageable grade
3/4 hematological toxicities. The ORR was encouraging
(54%) for this heavily pretreated population, and it was even
more striking in MCL (77%). The safety and biological activity inspired the Phase II clinical trial carried out by Wang
et al. in older (mean age 68 years) older patients with R/R
MCL. In this study, single-agent ibrutinib (560 mg/day) was
given to 111 patients until progression or until unacceptable
adverse events occurred. Ibrutinib achieved an ORR of 68%,
mostly driven by PR (47%), and a median DOR of 17.5 months
[66]. After a median follow-up of 26.7 months, the 2-year
median PFS and OS were 31% and 47%, respectively. The
most common adverse events were diarrhea (50%), fatigue
(50%), nausea (33%), and dyspnea (32%), and the most
prevalent grade 3 adverse events were hematological
[66,154]. Two categories of clinically relevant adverse
events emerged during the trial: bleeding episodes and
atrial fibrillation. Overall, half of the patients experienced
at least one bleeding event during the study period; however, most of them were grade 1/2 contusions, epistaxis,
and petechias, with only 2% of grade 3 episodes (subdural
hematoma and hematuria), without any fatal events
[66,155]. Regarding atrial fibrillation, there were 12 new
episodes recorded (11%), seven of which were grade 3,
and mostly occurred in patients with previous cardiovascular risk factors. Among the patients who experienced these
adverse events, only one needed ibrutinib dose reduction
and two required treatment discontinuation due to subdural
bleeding [155]. Based on these data, ibrutinib was granted
accelerated US Food and Drug Administration approval for
the treatment of R/R MCL patients who have received at
least one prior line of therapy. With longer follow-up it is
apparent, however, that most patients will ultimately
relapse following ibrutinib, some with more aggressive and
highly chemotherapy refractory disease [154,156]. At present, an elevated Ki-67 (>50%) appears to be the primary
feature associated with a reduced likelihood of response.
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Attempts to circumvent resistance by coupling ibrutinib
with rituximab have shown higher response rates with overall good tolerability; however, there is insufficient followup to gauge duration of response. Similarly, a large randomized study of bendamustine and rituximab given with or
without ibrutinib has recently been completed, and these
data are highly anticipated. Finally, second generation
BTK inhibitors, including ACP-196, are now under active
study in the clinic, with the potential to improve the
adverse event profile while capitalizing on a similarly pronounced response rate.

Role of hematopoietic stem cell
transplantation in R/R MCL: old habits die hard
Despite intensive and/or prolonged CIT approaches with or
without the inclusion of novel agents, we have yet to
achieve a permanent cure for patients with MCL, more concretely in R/R disease, for which tumoral progression is certain and often fatal. Although the addition of rituximab
improves the clinical outcomes of front-line regimens in
MCL [13,35,89,127], before the advent of targeted therapies, patients with R/R MCL after high-dose CIT and ASCT
had limited options for prolonged disease control, paired
with high toxicity of salvage therapy strategies [13,157].
Initial results of small retrospective series using high-dose

Fig. 1

chemotherapy and ASCT in the R/R setting were disappointing. For instance, the MD Anderson group reported the
single-institution outcomes of 121 MCL patients who underwent hematopoietic stem cell transplantation (HSCT), and
found that the 6-year PFS and OS for patients treated with
ASCT in the R/R setting were significantly inferior compared
to ASCT in first remission [158]. Nonetheless, in the largest
analysis of transplanted chemotherapy sensitive MCL
patients (n = 519) done through the Center for International
Blood & Marrow Transplant Research (CIBMTR), the 132
patients who received ASCT for R/R disease had a 5-year
OS of 44% with a 1 year nonrelapse mortality (NRM) of 9%
[159]. Although ASCT in chemosensitive MCL could offer
some clinical benefit in the R/R setting, recent expert
guidelines fail to give concise recommendations regarding
the role of ASCT in R/R disease [160].
Even with the risk of short-term severe complications
(i.e., NRM) and chronic toxicity (chronic graft vs. host disease), allogeneic HSCT (allo-HSCT) is recognized as a possible curative intervention for both R/R indolent and highgrade NHL due to the putative beneficial role of a tumorfree graft, and the well described graft versus lymphoma
effect [161–164]. Importantly, the use of nonmyeloablative
(NST)/reduced intensity conditioning (RIC) regimens has
broadened the applicability of allo-HSCT due to its lower
toxicity while maintaining the graft versus lymphoma effect
[164,165]. The use of allo-HSCT in R/R MCL was originally

Risk-directed therapy for mantle cell lymphoma.

Note: Allo-HSCT = allogeneic hematopoietic stem cell transplant; ASCT = autologous stem cell transplant; BR = bendamustine and rituximab;
HD = high dose; MCL = mantle cell lymphoma; R-BAC = rituximab, bendamustine, cytarabine; RCbl = rituximab and chlorambucil;
R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CVP = rituximab, cyclophosphamide, vincristine and
prednisone; R DHAP = rituximab, dexamethasone, cytarabine and cisplatin; R-HyperCVAD = rituximab, hyperfractionated cyclophosphamide,
vincristine, doxorubicin, dexamethasone; RM = rituximab maintenance; VcR-CVAD = bortezomib, rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; VR-CAP = bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone.

Mantle cell lymphoma
described in a retrospective study of 33 patients treated
with NST allo-HSCT whom achieved a 2-year PFS and OS of
60% and 65%, respectively, along with an NRM of 24%
[157]. Tam et al. [158] reported encouraging outcomes of
35 patients with R/R MCL treated with NST allo-HSCT with
a striking 6-year PFS and OS of 46% and 53%, paired with a
1-year NRM of 9%. Most importantly, plateaus in both PFS
and OS were annotated in nine patients whom had >5 years
of follow-up (63–110 months). The large CIBMTR series by
Fenske et al. [159] also analyzed the outcomes of RIC alloHSCT in chemotherapy sensitive R/R MCL and noticed a 5year OS and PFS of 31% and 24%, respectively, which were
not significantly different from the outcomes in patients
with R/R disease treated with ASCT. These results are probably explained by higher early NRM (17%) with lower rates of
relapse/progression (5-year rates 38%) in allo-HSCT patients
[159]. Last but not least, Hamadani et al. [164] assessed the
role of allo-HSCT in 202 patients with exclusively chemorefractory R/R MCL. Despite the fact that almost 60% of
patients received NST/RIC, there were no significant differences noted in 3-year rates of NRM, PFS, and OS between
the above patients and the ones conditioned with myeloablative regimens (43% vs. 47%, p = 0.68; 25% vs. 20%, p = 0.53;
30% vs. 25%, p = 0.45; respectively) [164]. This study demonstrated that in patients eligible for aggressive salvage regimens, allo-HSCT can provide long-term disease control in
approximately one-third of heavily pretreated chemorefractory R/R MCL. In the R/R MCL setting, we concur with recent
consensus guidelines that proposed using RIC allo-HSCT in
eligible patients with a suitable donor after achieving at
least a second PR with reinduction CIT, particularly in those
with features that predict for longer disease control (e.g.,
disease recurrence >1 year after ASCT) [160].
Recent innovative cellular therapeutic approaches, such
as chimeric antigen receptor (CAR) T cells may also prove to
be effective and safe in the R/R MCL population [166]. CAR
T cells are genetically modified autologous T cells designed
(at present) to target and proliferate upon engagement of
CD19. Early data suggest high remission rates, which may
serve as a quintessential bridge for transplantation [167–
169]. Nonetheless, CAR-T therapy in R/R MCL is still experimental and has not demonstrated prolonged disease remissions leading to potential cures, which can be occasionally
obtained with allo-HSCT [161–164].

Conclusions
Patients with MCL have a heterogeneous clinical evolution
that can present as slow progressors with an indolent tumor,
or as aggressive debutantes with a florid disease in need of
prompt treatment. For many years, advances in MCL lagged
behind those for other NHLs; however, the past decade has
given us improved tools for prognostication and novel therapeutics that are facilitating meaningful improvements in
the life expectancy of patients. Our proposed therapeutic
approach for patients with both newly diagnosed and R/R
MCL is illustrated in Fig. 1. Treatment selection should not
only be based on age cutoffs or clinical presentations, but
on the evaluation of biological factors, such as the Ki-67
proliferative index, so that the intensity of therapy is
rationally coupled to both the aggressiveness of the under-
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lying MCL and the capacity for the patient to safely receive
such therapy. The advent of novel therapies has already
yielded considerable benefit for those with relapsed and
refractory MCL, and their utility in frontline combinations
is becoming increasingly apparent. In this context, it is
important to recognize that these novel agents are for the
first time facilitating a deintensification of care for those
with newly diagnosed disease, allowing for both extended
disease control and an improvement in toxicity. Treatments
such as BR, R2, VR-CAP, and ibrutinib-based regimens exemplify these approaches. Integration of rituximab maintenance following chemotherapy, and possibly autologous
transplantation, has been shown across studies to prolong
remission duration, and serves perhaps as the first standard
of care for MCL patients.
Unfortunately, relapse is an inevitable outcome in MCL,
and may be accompanied by more aggressive and
chemotherapy refractory disease. However, we can now
appreciate that our armamentarium is improving. Noteworthy in this regard are phosphatidylinositol 3-kinase/DNA
protein kinase inhibitors, selective histone deacetylase inhibitors, next-generation IMIDs (pleotropic protein modifiers),
oral and irreversible proteasome inhibitors, and novel
immunotherapeutic approaches, such as CAR-T cells, checkpoint inhibitors, and haploidentical allogeneic transplantation. The future of MCL is a bright one, and one in which
we may realistically reappraise this disease as a truly indolent lymphoma.
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